Rheumnow Podcast

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com Join us at RheumNow Live February 8 & 9 in Dallas, TX!  https://t.co/7WawLxwBLP

This year at ACR24, the RheumNow faculty and reporters were prolific, generating 800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days!  You can best review and learn ACR 2024 by A) Rheumatology Roundup; b) TOPIC Panel podcasts; and c) Topic podcasts. This weeks notable citations on RheumNow.com

Brian Joros, a faculty expert in rheumatology at Northwestern University, and Peter Nash from Griffith University in Brisbane join the discussion. They dive into breakthrough advancements in targeting the IL-17 pathway for rheumatic diseases. Insights from the ACR Annual Meeting reveal impressive MRI remission rates with bemikizumab for ankylosing spondylitis. The duo also explores innovations in psoriatic arthritis treatments, addressing effectiveness, safety, and the nuances of treatment switches during flare-ups, making a case for the evolution of IL-17 therapies.

David Liew, a renowned rheumatologist from Melbourne, joins an expert panel to discuss groundbreaking findings from the ACR Annual Meeting. They explore the effectiveness of Upadacitinib for treating giant cell arteritis and the complexities surrounding patient enrollment for trials. The conversation shifts to the skepticism around methotrexate for polymyalgia rheumatica and the potential of JAK inhibitors in myositis. Safety concerns regarding these therapies, particularly in cardiovascular health, underscore the importance of ongoing research.

Rheumatologists Eric Dein from Atlantic Health, Jiha Lee from the University of Michigan, and Jeffrey Spark from Harvard Medical School dive into crucial topics surrounding rheumatoid arthritis. They discuss the importance of statin prescription amidst cardiovascular risks and the challenges of steroid use, particularly for elderly patients. Innovations in remote monitoring with smartphone technology and AI are highlighted, alongside a study aimed at improving fertility for women with RA, showcasing advancements in tailored treatment strategies.

Join Artie Kavanaugh, a rheumatologist from UC San Diego, and Quillen Connelly from Galway Clinic, as they delve into the intricate realm of psoriatic arthritis. They discuss the rising placebo response rates tied to socioeconomic factors and the urgent need for gender-specific research in treatment. Artie breaks down the potential of combination therapies, while Quillen shares insights on the durable effectiveness of bimikizumab. Together, they illuminate the latest advancements in diagnosis and treatment, providing a comprehensive overview for clinicians.

Dive into the highlights from the ACR 2024 meeting in Washington, DC, featuring exciting advancements in rheumatology treatments. Discover innovative therapies for conditions like rheumatoid arthritis and lupus, as well as the environmental impact of adalimumab and its biosimilars. Learn about the promising effects of GLP-1 drugs and groundbreaking AI-driven ultrasound technology in diagnostics. The discussion wraps up with upcoming events for networking and collaboration in the field. Tune in for a mix of insights and practical updates!

In this engaging discussion, Lihi Eder, an expert in psoriatic arthritis from the University of Toronto, Sheila Reyes, a Filipino rheumatologist, and Adela Castro, a clinical assistant professor in Memphis, tackle the latest breakthroughs in spondyloarthritis. They dive into challenges in diagnosing axial spondyloarthritis and the importance of updated classification criteria. Gender differences in treatment responses and personalized approaches are highlighted, along with insights on treatment failures and strategic switches between biologic therapies. Tune in for essential insights!

A New ACR Cancer Survival in RA "Changing Mindsets about Methotrexate Side Effects" Control RA, Build Stronger Bones Cumulative Steroid Use and Cardiovascular Events Disease Activity in RA-ILD Do TNFis and JAKis Prevent Cancer!? Estimating Inflammation, Damage and Patient Distress Finding the Right Combination Therapy in RA Implantable Vagus Nerve Stimulator for RA Is Frequent Lab Monitoring Necessary? Long Term Follow up from APIPPRA Metabolic Dysregulation and RA Interstitial Lung Disease Native Americans with RA Die Young Paraoxonase-1: Possible Biomarker for Progression to RA Pred Softly: Steroids Predicting Flares in Rheumatoid Arthritis RA Roundup: Is LDA Inappropriate? What about Statins for JAKs? RA Treatment Adherence: Is decision making really shared? RA: One JAK to Rule Them All? Sonelokimab in PsA: Phase 2 Data Treat-to-Target Improves Fertility in Women with RA Treatment Considerations for RA-ILD Treatment Strategies in RA Use of AI in Hand Ultrasound Scoring Vaccine Responses:The DMARD Counts What's New in Relapsing Polychondritis? What's The State of Biosimilars?

In this engaging discussion, Philip Meese, a seasoned rheumatologist, delves into the latest advancements in IL-17 treatments for psoriatic arthritis and axial spondyloarthritis. He shares intriguing real-world data on the efficacy and safety of Bimekizumab, highlighting significant improvements in pain and fatigue. The conversation also explores treatment strategies comparing TNF and IL-17 inhibitors, revealing insights from a large patient study. Additionally, Meese discusses the long-term safety profile of Bimekizumab and other emerging therapies, emphasizing personalized patient care.